Challenges and potential for RNA nanoparticles (RNPs)

Journal of Biomedical Nanotechnology

Volumn 5, Issue 1, 2009, Pages 36-44

  Davis, D ^a   Akhtar, U ^a   Keaster, B ^a   Grozinger, K ^a   Washington, L ^a   Kelsey, S ^a   Sarkar, A ^b   DeLong, R K ^a  

^a MISSOURI STATE UNIVERSITY   (United States)

^b CATHOLIC UNIVERSITY OF AMERICA   (United States)

Author keywords

Delivery; Nanoparticles (NPs); Polyamidoamine (PAMAM); Protamine; siRNA; Splice site switching oligomer (SSO)

Indexed keywords

DELIVERY; POLYAMIDOAMINE (PAMAM); PROTAMINE; SIRNA; SPLICE-SITE SWITCHING OLIGOMER (SSO);

BINDING SITES; GENES; NUCLEIC ACIDS; OLIGOMERS; OLIGONUCLEOTIDES; RNA; SANITARY SEWERS;

NANOPARTICLES;

ALUMINUM; BERYLLIUM; COPPER; DOUBLE STRANDED RNA; GOLD; GOLD NANOPARTICLE; IRON; MACROGOL; NANOPARTICLE; NICKEL; OLIGONUCLEOTIDE; PENETRATIN; POLYAMIDOAMINE; PROTAMINE; RNA; SILICON; SILVER; SMALL INTERFERING RNA; TITANIUM; TRANSACTIVATOR PROTEIN;

COMPUTER SIMULATION; CONJUGATION; ENZYME STABILITY; GENE TARGETING; GENETIC STABILITY; HUMAN; IMMUNOMODULATION; MOLECULAR MODEL; NONHUMAN; REVIEW; RNA BINDING; RNA SPLICING; RNA STABILITY;

DRUG CARRIERS; DRUG COMPOUNDING; NANOMEDICINE; NANOPARTICLES; RNA; TRANSFECTION;

EID: 67649779613     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2009.1005     Document Type: Review

References (83)

1. R. Esfand and D. Tomalia, Poly(amidoamine) (PAMAM) dendrimers: From biomimicry to drug delivery and biomedical applications. Drug Discovery Today 6, 427 (2001).
2. D. LaVan, T. McGuire, and R. Langer, Small-scale systems for in vivo drug delivery. Nat. Biotechnol. 10, 1184 (2003).
3. Z. Liu, W. Cai, L. He, N. Nakayama, K. Chen, X. Sun, and H. Dai, In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat. Nanotechnol. 1, 47 (2007).
4. J. Rolland, B. Maynor, W. Euliss, A. Exner, E. Denison, and J. DeSimone, Direct fabrication and harvesting of monodisperse, shape specific nano-biomaterials. J. Am. Chem. Soc. 127, 10096 (2005).
5. S. Son, X. Bai, A. Nan, H. Ghandehari, and S. Lee, Template synthesis of multifunctional nanotubes for controlled release. J. Controlled Release 114, 143 (2006).
6. Z. Cui, L. Baizer, and R. Mumper, Intradermal immunization with novel plasmid DNA-coated nanoparticles via a needle-free injection device. J. Biotech. 102, 105 (2003).
7. X. Zhou, X. Zhang, X. Yu, X. Zha, Q. Fu, B. Liu, X. Wang, Y. Chen, Y. Shan, and Y. Jin, The effect of conjugation to gold nanoparticles on the ability of low molecular weight chitosan to transfer DNA vaccine. Biomaterials 29, 111 (2008).
8. A. Fougerolles, Delivery vehicles for small interfering RNA in vivo. Hum. Gene. Ther. 19, 125 (2008).
9. R. Schiffelers, A. Ansari, J. Xu, Q. Zhou, Q. Tang, G. Storm, G. Molema, P. Y. Lu, P. V. Scaria, and M. C. Woodle, Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32, 19 (2004).
10. J. Roberts, E. Palma, P. Sazani, H. Ømm, M. Cho, and R. Kole, Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. Mol. Ther. 14, 471 (2006).
11. P. Guterstam, M. Lindgren, H. J. Johansson, U. Tedebark, J. Wengel, S. El-Andaloussi, and U. Langel, Splice switching efficiency and specificity for oligonucleotides with locked nucleic acid monomers. Biochem. J. 2, 307 (2008).
12. K. Warfield, R. G. Panchal, M. J. Aman, and S. Bavari, Antisense treatments for biothreat agents. Curr. Opin. Mol. Ther. 8, 93 (2006).
13. K. Spurgers, C. M. Sharkey, K. L. Warfield, and S. Bavari, Oligonucleotide antiviral therapeutics: Antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res. 78, 26 (2008).
14. J. Davies, Microbes have the last word. A drastic re-evaluation of antimicrobial treatment is needed to overcome the threat of antibiotic-resistant bacteria. EMBO Reports 8, 616 (2007).
15. H. Lage, ABC-transporters: Implications on drug resistance from microorganisms to human cancers. Int. J. Antinzicrob. Agents 22, 188 (2003).
16. R. K. DeLong, H. Yoo, S. K. Alahari, M. Fisher, S. M. Short, S. H. Kang, R. Kole, V. Janout, S. L. Regan, and R. L. Juliano, Novel cationic amphiphiles as delivery agents for antisense oligonucleotides. Nucleic Acids Res. 16, 3334 (1999).
17. P. Miller, G. Bi, S. A. Kipp, V. Fok, and R. K. DeLong, Triplex formation by a psoralen-conjugated oligodeoxyribonucleotide containing the base analog 8-oxo-adenine. Nucleic Acids Res. 24, 30 (1996).
18. H. Kang, R. K. DeLong, M. H. Fisher, and R. L. Juliano, Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm. Res. 12, 2099 (2005).
19. K. Nauwelaerts, M. Fisher, M. Froeyen, E. Lescrinier, A. Van Aerschot, D. Xu, R. K. DeLong, H. Kang, R. L. Juliano, and P. Herdewijn, Structural characterization and biological evaluation of small interfering RNAs containing cyclohexenyl nucleosides. J. Am. Chem. Soc. 129, 9340 (2007).
20. R. Knowle, A. Werner, and R. K. DeLong, R4 peptide-pDNA nanoparticle coated HepB vaccine microparticles: Sedimentation, partitioning, and spray freeze dry bioprocesses. J. Nanosci. Nanotechnol. 9, 2783 (2006).
21. R. K. Delong and P. S. Miller, Inhibition of human collagenase activity by antisense oligonucleoside methylphosphonates. Antisense Nucleic Acid Drug Dev. 4, 273 (1996).
22. A. Nolting, R. K. DeLong, M. H. Fisher, E. Wickstrom, G. M. Pollack, R. L. Juliano, and K. L. Brouwer, Hepatic distribution and clearance of antisense oligonucleotides in the isolated perfused rat liver. Pharm. Res. 4, 516 (1997).
23. S. Alahari, R. K. DeLong, M. H. Fisher, N. M. Dean, P. Viliet, R. L. Juliano, Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. J. Pharmacol. Exp. Ther. 1, 419 (1998).
24. S. Elumalai, R. K. Delong, and Q. Rongda, Protamine mediated gene delivery improves bombardment transformation efficiency in plant cells. Plant Cell Reports, published in-online, November (2008).
25. P. Medberry, S. Dennis, T. Van Hecke, and R. K. DeLong, pDNA bioparticles: Comparative heterogeneity, surface, binding, and activity analyses. Biochem. Biophys. Res. Commun. 319, 426 (2006).
26. C. Lam, J. T. James, R. McCluskey, S. Arepalli, and R. L. Hunter, A review of carbon nanotube toxicity and assessment of potential occupational and environmental health risks. Crit. Rev. Toxicol. 36, 189 (2006).
27. L. Renwick, D. Brown, A. Clouter, and K. Donaldson, Increased inflammation and altered macrophage chemotactic responses caused by two ultrafine particle types. Occup. Environ. Med. 6, 442 (2004).
28. J. Dong, D. Wang, F. Van Ginkel, D. W. Pascual, and R. A. Frizzell, Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector. Hum. Gene. Ther. 10, 319 (1996).
29. S. Audouy, L. F. de Leij, D. Hoekstra, and G. Molema, In vivo characteristics of cationic liposomes as delivery vectors for gene therapy. Pharm. Res. 19, 1599 (2002).
30. J. Zhang, F. Liu, and L. Huang, Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv. Drug Deliv. Rev. 57, 689 (2006).
31. V. Stone, J. Shaw, D. Brown, M. MacNee, W. Faux, and K. Donaldson, The role of oxidative stress in the prolonged inhibitory effect of ultrafine carbon black on epithelial cell function. Toxicol. In vitro. 12, 649 (1998).
32. B. Merchant, Gold, the Noble metal and the paradoxes of its toxicology. Biologicals 26, 49 (1998).
33. Y. J. Park, L. C. Chang, J. F. Liang, C. Moon, C. P. Chung, and V. C. Yang, Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: In vitro and in vivo study. Faseb J. 11, 1555 (2005).
34. R. K. DeLong, Applications-Materials, formulation processes and characterization chemistry of DNA and siRNA nanoparticles, Handbook of Particulate Drug Delivery, edited by H. S. Nalwa, American Scientific Publishers (2008), Vol.2, pp. 1687-11682
35. L. Zhi, J. Rongchaoin, A. Chad, and R. L. Letsinger, Multiple thiolanchor capped DNA-gold nanoparticle conjugates, Nucleic Acids Res. 30, 1558 (2002).
36. N. Kossovsky, H. J. Hnatyszyn, and A. Gelman, Targeted transfection nanoparticles. US Patent #5460831, (1995), October.
37. A. Cai, An electrochemical DNA hybridization detection assay based on a silver nanoparticle label. Analyst 127, 803 (2002).
38. S. Dworetzky and C. M. Feldherr, Translocation of RNA-coated gold particles through the nuclear pores of oocytes. J. Cell Biol. 106, 575 (1988).
39. A. Kumar and A. Jakhmola, RNA-mediated fluorescent Q-PbS nanoparticles. The American Chemical Society of Surfaces and Colbids 23, 2916 (2007).
40. 3 nanoparticles by using a multifunctional polymeric linker. Small 3, 1374 (2007).
41. J. Kim, R. Estabrook, G. Braun, B. Lee, and N. Reich, Specific and sensitive detection of nucleic acids and RNases using gold nanoparticle-RNA- fluorescent dye conjugates. Chem. Commun. 4342 (2007).
42. S. Li, Y. Chen, M. Hackett, and L. Huang, Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol. Ther. 1, 163 (2008).
43. W. Moll and P. Guo, Grouping of ferritin and gold nanoparticles conjugated to pRNA of the phage phi29 DNA-packaging motor. J. Nanosci. Nanotechnol. 9, 3257 (2007).
44. S. Phadtare, V. P. Vinod, K. Mukhopadhyay, A. Kumar, M. Rao, R. V. Chaudhari, and M. Sastry, Immobilization and biocatalytic activity of fungal protease on gold nanoparticle-loaded zeolite microspheres. Biotech. and Bioengineering 85, 629 (2004).
45. P. Asuri, S. Sandeep, A. Alexey, S. Jonathan, S. Ravi, and J. Kane, Enhanced stability of enzymes adsorbed onto nanoparticles. J. Nanosci. Nanotechnol. 5, 1675 (2006).
46. S. Futaki, T. Suzuki, W. Ohashi, T. Yagami, S. Tanaka, K. Ueda, and Y. Sugiura, Arginine-rich peptides. J. Biol. Chem. 276, 5836 (2001).
47. M. Gottfried, V. Vogel, J. Weyermann, D. Lochmann, A. Jacomina, C. Tziatzios, W. Haase, D. Wouters, S. Ulrich, A. Zimmer, J. Kreuter, and D. Schubert, Oligonucleotide-protamine-albumin nanoparticles: Protamine sulfate causes drastic size reduction. J. Controlled Release 106, 1 (2005).
48. T. Shiraishi and P. E. Nielsen, Enhanced delivery of cell-penetrating peptide-peptide nucleic acid conjugates by endosomal disruption. J. Biotech. 129, 10 (2007).
49. M. Patil, M. Zhang, S. Betigeri, O. Taratula, H. He, and T. Minko, Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. Bioconjug. Chem. 19, 1396 (2008).
50. D. Hiraiwa, T. Yoshimura, and K. Esumi, Interaction forces between poly(amidoamine) (PAMAM) dendrimers adsorbed on gold surfaces. J. Colloid Interface Sci. 298, 982 (2006).
51. J. Yan, R. Kawamura, and J. F. Marko, Statistics of loop formation along double helix DNAs. Phys. Rev. E 4 Stat. Nonlin. Soft Matter Phys. 7, 10 (2005).
52. V. Bloomfield, DNA condensation by multivalent cations. Biopolymers 44, 269 (1997).
53. C. Bustamante, Z. Bryant, and S. B. Smith, Ten years of tension: Single-molecule DNA mechanics. Nature 1, 423 (2003).
54. A. Mariano, G. Blanco, A. P. Baraniak, and E. L. Lasda, Alternative splicing in disease and therapy. Nat. Biotechnoh 22, 535 (2004).
55. A. Ghosh, D. Stewart, and G. Matlashewski, Regulation of human p53 activity and cell localization by alternative splicing. Mol. Cell. Biol. 24, 7987 (2004).
56. C. Papin, A. Denouel-Galy, D. Laugier, G. Calothy, and A. Eychène, Modulation of kinase activity and oncogenic properties by alternative splicing reveals a novel regulatory mechanism for B-Raf. J. Biol. Chem. 2, 10 (1998).
57. H. Byun, I. K. Hong, E. Kim, Y. J. Jin, D. I. Jeoung, J. H. Hahn, Y. M. Kim, S. H. Park, and H. Lee, A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways. J. Biol. Chem. 281, 34833 (2006).
58. N. Iwanaga, M. Kamachi, K. Aratake, Y. Izumi, H. Ida, F. Tanaka, M. Tamai, K. Arima, H. Nakamura, T. Origuchi, A. Kawakami, and K. Eguchi, Regulation of alternative splicing of caspase-2 through an intracellular signaling pathway in response to pro-apoptotic stimuli. J. Lab. Clin. Med. 14, 105 (2005).
59. D. Purcell and M. A. Martin, Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J. Virol. 6, 6365 (1993).
60. T. Heise, G. Sommer, K. Reumann, I. Meyer, H. Will, and H. Schaal, The hepatitis B virus PRE contains a splicing regulatory element. Nucleic Acids Res. 12, 353 (2006).
61. S. Kang, M. J. Cho, and R. Kole, Up-regulation of luciferase gene expression with antisense oligonucleotides: Implications and applications in functional assay development. Biochemnistry 5, 6235 (1998).
62. S. Resina, R. Kole, A. Travo, B. Lebleu, and A. R. Thierry, Switching on transgene expression by correcting aberrant splicing using multi-targeting steric-blocking oligonucleotides. J. Gene. Med. 9, 498 (2007).
63. 3 nanocrystals: A tool for targeting cell surface receptors. Angew. Chem. Int. Ed. Engl. 47, 4748 (2008).
64. J. Hill, T. Ichim, K. Kusznieruk, M. Li, X. Huang, X. Yan, R. Zhong, E. Cairn, D. Bell, and W. P. Min, Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J. Immunology 171, 691 (2003).
65. G. Liu, H. Ng, Y. Akasaki, X. Yuan, M. Ehtesham, D. Yin, K. Black, J. Yu, Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response. European J. Immunology 34, 1680 (2004).
66. H. Fletcher, P. Owiafe, D. Jeffries, P. Hill, G. A. Rook, A. Zumla, T. M. Doherty, and R. H. Brookes, Vacsel study group. Increased expression of mRNA encoding interleukin (IL)-4 and its splice variant IL-4delta2 in cells from contacts of Mycobacterium tuberculosis, in the absence of in vitro stimulation. Immunology 4, 669 (2004).
67. M. Robbins, A. Judge, E. Ambegia, C. Choi, E. Yaworski, L. Palmer, K. McClintock, and I. Maclachian, Misinterpreting the therapeutic effects of siRNA caused by immune stimulation. Hum. Gene. Ther. (2008), August. [Epub ahead of print]
68. K. Sanjay Singh, and S. Prakash Bisen, Adjuvanticity of stealth liposomes on the immunogenicity of synthetic gp41 epitope of HIV-1, Vaccine 3, 4161 (2006).
69. A. Vila, A. Sánchez, C. Évora, I. Soriano, O. McCallion, and M. J. Alonso, PLA-PEG particles as nasal protein carriers: The influence of the particle size. Int. J. Pharm. 292, 43 (2005).
70. B. Shi, C. Fang, M. X. You, M. H. Hong, and Y. Y. Pei, Stealth PEGPHDCA niosomes: Effects of chain length of PEG on niosomes in vitro complement consumption and phagocytic uptake. Yao Xue Xue Bao 11, 976 (2005).
71. T. I. Kim, H. J. Seo, J. S. Choi, H. S. Jang, J. U. Baek, K. Kim, and J. S. Park, PAMAM-PEG-PAMAM: Novel triblock copolymer as a biocompatible and efficient gene delivery carrier. Biomacromobecules 5, 2487 (2004).
72. P. Jevprasesphant, J. Penny, R. Jalal, D. Attwood, N. McKeown, and A. D'Emanuele, The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int. J. Pharm. 252, 263 (2003).
73. M. Bouxsein, McAllister, Ewert, Samuel, and Safinya, Structure and gene silencing activities of monovalent and pentavalent cationic lipid vectors complexed with siRNA. Biochemistry 46, 4785 (2007).
74. R. Kostiainen and A. Mauri, Precisely defined protein-polymer conjugates: Construction of synthetic DNA binding domains on proteins by using multivalent dendrons. ACS Nano. 1, 103 (2007).
75. A. Zelikin and N. Alexander, A General approach for DNA encapsulation in degradable polymer microcapsules. ACS Nano. 1, 63 (2007).
76. Y. Chang and B. Connie, Curvature dependence of viral protein structures on encapsidated nanoemulsion droplets. ACS Nano. 2, 281 (2008).
77. M. Rod, Nanomedicine: Sizing up targets with nanoparticles. Nat. Nanotechnol. 3, 12 (2008).
78. D. Peer, Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751 (2007).
79. M. K. Calabretta, A. Kumar, A. M. McDermott, and C. Cai, Antibacterial activities of poly(amidoamine) dendrimers terminated with amino and ply(ethylene glycol) groups. Biomacromolecules 8, 1807 (2007).
80. R. Martin and R. Charles, The emerging field of nanotube biotechnology. Nat. Rev. Drug Discovery 2, 29 (2003).
81. B. Panchapakesan, S. Lu, K. Sivakumar, K. Taker, G. Cesarone, and E. Wickstrom, Single-wall carbon nanobomb agents for killing breast cancer cells. NanoBiotech. 1, 133 (2005).
82. S. Kang, M. Pinault, L. D. Pfefferle, and M. Elimelech, Single-walled carbon nanotubes exhibit strong antimicrobial activity. Langinir 23, 8670 (2007).
83. J. Hernández-Sierra, F. Ruiz, D. C. Cruz Pena, F. Martínez-Gutiérrez, A. E. Martínez, J. Pozos, A. Guillén, H. Tapia-Pérez, and G. M. Castañón, The antimicrobial sensitivity of Streptococcus mutans to nanoparticles of silver, zinc oxide, and gold. Nanomedicine 2, 112 (2008).